How to Buy Arcturus Therapeutics Holdings Stock
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.
Arcturus Therapeutics Holdings stock last closed at $12.17, up 10.64% from the previous day, and has decreased 55.03% in one year. It has overperformed other stocks in the Biotechnology industry by 0.22 percentage points. Arcturus Therapeutics Holdings stock is currently +51.37% from its 52-week low of $8.04, and -72.96% from its 52-week high of $45.00.
As of Apr 22, 2025, there are 27.12M shares of ARCT outstanding. The market capitalization of ARCT is $330.05M. In the last 24 hours, 459,580 ARCT shares were traded.
How to Buy Arcturus Therapeutics Holdings Stock
Wondering how to invest in Arcturus Therapeutics Holdings stock? Here's how.
- Choose where to buy Arcturus Therapeutics Holdings stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you decide where to buy Arcturus Therapeutics Holdings stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your investment account: Select your payment method and add your details.
- Research Arcturus Therapeutics Holdings stock: The Arcturus Therapeutics Holdings ticker symbol is ARCT. Is Arcturus Therapeutics Holdings stock a good investment? Should you buy shares of ARCT? How do ARCT's underlying business fundamentals look? Do top analysts think Arcturus Therapeutics Holdings is a good buy? Why has ARCT's stock price moved recently? (Hint: Our stock research tools can help you decide if ARCT is a good stock to buy).
- Make your ARCT purchase: Decide if you will purchase ARCT shares at the current market price or use a limit order to purchase ARCT stock at a particular price.
- Track your investment in ARCT: Create a watchlist to keep tabs on your investment in Arcturus Therapeutics Holdings shares.
Step 1: Choose where to buy Arcturus Therapeutics Holdings stock
You need a brokerage account in order to access the NASDAQ market and buy ARCT shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global financial markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal details so you are able to invest in ARCT today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create a new brokerage account.
- Submit your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've created your account on the best stock trading app, you need to deposit funds:
Check out this video walkthrough if you need help transferring funds into your new brokerage account.
Step 4: Research Arcturus Therapeutics Holdings stock
After you have identified the best place to buy Arcturus Therapeutics Holdings stock, it's crucial to evaluate their stock before you buy, so you can understand the risk as well as the opportunity.
Arcturus Therapeutics Holdings shares at a glance
Fundamentals of ARCT
WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on ARCT's stock page.
Is ARCT stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge ARCT's intrinsic value.
Using relative valuations methods:
- ARCT may be undervalued based on its P/B ratio of 1.37x, relative to Biotechnology industry P/B ratio of 4.16x
You can do more valuation research on ARCT's stock here.
How do ARCT Financials look?
Pros:
- ARCT has cash burn of 60395000. It has enough cash and short-term investments to cover this for at least one year.
- ARCT has $292.03M in cash and short term investments. This is enough to cover its annual cash burn of $60.40M.
- Total ARCT debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the ARCT balance sheet.
- There are more short-term assets than long-term liabilities on the ARCT balance sheet.
Cons:
- ARCT profit margin has gone down from -17.8% to -53.1% in the past year.
- ARCT has a relatively high debt to equity ratio of 0.43.
Is ARCT stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 4 Equities analysts who give ratings on ARCT, the consensus analyst rating on ARCT is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Arcturus Therapeutics Holdings stock forecast page.
ARCT Momentum
ARCT Revenue
Last year, ARCT revenue was $152.31M. Over the last 5 year, ARCT's revenue has grown by 48.93% per year. This was faster than the Biotechnology industry average of 44.4%.
Dive into ARCT's earnings and revenue performance here.
Latest Insiders Trades at ARCT
In the past year, executives and large shareholders at ARCT have sold more shares than they have bought.
Pad Chivukula, Chief Scientific Officer COO of ARCT, was the latest ARCT insider to sell. They sold $249,120.00 worth of ARCT shares on Oct 15, 2024.
Learn more about who owns ARCT shares here.
Can I get consistent income from ARCT stock?
No, Arcturus Therapeutics Holdings doesn't provide an income stream by paying out dividends.
ARCT Social Trading Data
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your ARCT purchase
You have two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, place a limit order.
Press the Open Trade button and your broker will execute your order.
If you want additional info about buying stocks on eToro, click the helpful video below:
Step 6: Track your investment in ARCT
Now that you own some ARCT stock, you'll want to stay up-to-date on your new shares.
Put ARCT on a watchlist to get notified of the latest news about your ARCT stock.
ARCT Feed
How to Buy Stock in Arcturus Therapeutics Holdings
To reiterate, here are the 6 steps you need to take to buy Arcturus Therapeutics Holdings stock right now:
- Choose where to buy Arcturus Therapeutics Holdings stock
- Create a brokerage account
- Fund your investment account
- Research Arcturus Therapeutics Holdings stock
- Make your ARCT purchase
- Track your investment in ARCT
If you require a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you want to get updates on your investment in Arcturus Therapeutics Holdings, click below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.